Immune checkpoint inhibitor (ICI)-based treatment beyond progression with prior immunotherapy in patients with stage IV non-small cell lung cancer: a retrospective study

BACKGROUND: Although immune checkpoint inhibitors (ICIs) provide unprecedented survival improvement for patients with advanced non-small cell lung cancer (NSCLC), disease progression inevitably occurs. After ICIs failure, limited data exist on whether ICI-based treatment beyond progression (TBP) may...

Descripción completa

Detalles Bibliográficos
Autores principales: Tian, Tian, Yu, Min, Yu, Yang, Wang, Ke, Tian, Panwen, Luo, Ziyue, Ding, Zhenyu, Wang, Ye, Gong, Youling, Zhu, Jiang, Zou, Bingwen, Sio, Terence T., Alves, Adelaide, Liu, Yongmei, Huang, Meijuan, Lu, You
Formato: Online Artículo Texto
Lenguaje:English
Publicado: AME Publishing Company 2022
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9271428/
https://www.ncbi.nlm.nih.gov/pubmed/35832458
http://dx.doi.org/10.21037/tlcr-22-376

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9271428/
https://www.ncbi.nlm.nih.gov/pubmed/35832458
http://dx.doi.org/10.21037/tlcr-22-376

Ejemplares similares